{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023229","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.809897+00:00","generated_at":"2026-06-22T03:22:41.953437+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical Q3 revenue $27.8M (+5.5% YoY); raises 2022 guidance to $111-113M","bullets":["Revenue $27.8M, +5.5% YoY and +10.8% QoQ; gross margin 15.6% vs 11.2% YoY.","Net loss ($40.8M) / ($0.85) per share; non-GAAP EPS ($0.70).","Raises FY2022 revenue guidance to $111M-$113M from $105M-$110M.","Awarded 5-year VA contract for Tablo at 106 VA hospitals and home settings.","Secured up to $300M in debt financing to strengthen balance sheet."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023229","json":"https://secwatch.observer/filing/0000950170-22-023229.json","markdown":"https://secwatch.observer/filing/0000950170-22-023229.md","text":"https://secwatch.observer/filing/0000950170-22-023229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017022023229/0000950170-22-023229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017022023229/om-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:22:41.953437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37cc40ee216f1fbabbc3a8af2c7a8e86aacef21a","claim":"Outset Medical, Inc. reported the third quarter ended September 30, 2022 results: revenue $27.8 million, net income ($40.8) million, EPS ($0.85) per share. Guidance raised.","evidence_excerpt":"specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Outset Medical Reports Third Quarter 2022 Financial Results Revenue Grows 10.8% from Q2 to $27.8 million; Gross Margin Expands to 15.6% 2022 Revenue Guidance Raised to $111 million to $113 million San Jose, CA – November 8, 2022 – Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017022023229/0000950170-22-023229-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$27.8 million"},{"label":"Net income","value":"($40.8) million"},{"label":"EPS","value":"($0.85) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}